Table 1.
Demographic and clinical characteristics of all subjects.
| Variable | Healthy control group (N = 57) | Chronic hepatitis B group (N = 254) | Cirrhosis group (N = 206) | Liver cancer group (N = 127) | Statistical value | P | |
|---|---|---|---|---|---|---|---|
| Age (years) | 38 (32.5–52.5) | 39 (34–49) | 49 (41–57) | 54 (45–60) | 106.08* | < 0.0001 | |
| Gender (Male/Female) | Female (%) | 24 (12.31) | 106 (54.36) | 48 (24.62) | 17 (8.72) | 41.48# | < 0.0001 |
| Male (%) | 33 (7.35) | 148 (32.96) | 158 (35.19) | 110 (24.50) | |||
| AST (U/L) | 18 (15–23.5) | 25 (21–33.25) | 31 (25–45.25) | 36 (26–59) | 117.75* | < 0.0001 | |
| ALT/(U/L) | 17 (11–24) | 26 (17–43) | 30 (23–44) | 37 (23–58) | 69.11* | < 0.0001 | |
| TBIL (umol/L) | 12.4 (9.85–17.15) | 13.9 (10.7–18.3) | 17.15 (11.9–25.4) | 10.9 (7.9–17.7) | 53.30* | < 0.0001 | |
| HBV DNA (log10IU/ml) | NA | 2.7 (1.3–3.31) | 2.7 (1.33–2.84) | 3.17 (2.7–5.01) | 50.04* | < 0.0001 | |
| HBsAg (log10IU/ml) | NA | 3.33 (2.76–3.77) | 3.03 (2.45–3.31) | 2.98 (2.15–3.31) | 34.43* | < 0.0001 | |
| AFP (ng/ml) | 2.2 (1.45–3.45) | 2.5 (1.8–3.73) | 3 (2–5.7) | 30.9 (4–612.9) | 138.78* | < 0.0001 | |
AST aspartate aminotransferase; ALT alanine aminotransferase; TBIL total bilirubin; HBV-DNA hepatitis B virus DNA; HBsAg hepatitis B surface antigen; AFP alpha-fetoprotein; NA not applicable; *: Kruskal–Wallis test; #: Chi-square test.